JOHN STEELE: Open Payments
NPI 1942350616 · WEST COLUMBIA, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,897 in 113 payments from 13 companies in 2025. Trend: 2023 $1,812 · 2024 $1,589 · 2025 $1,897
Food & beverage: $1,897
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 18 | $322 |
| Vanda Pharmaceuticals Inc. | 9 | $252 |
| Otsuka America Pharmaceutical, Inc. | 11 | $220 |
| ABBVIE INC. | 24 | $203 |
| Alkermes, Inc. | 8 | $178 |
| Teva Pharmaceuticals USA, Inc. | 15 | $155 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $155 |
| Lundbeck LLC | 9 | $154 |
| Bausch Health US, LLC | 5 | $121 |
| Almatica Pharma LLC | 4 | $60 |
Products named: REXULTI, INGREZZA, HETLIOZ, VRAYLAR, ARISTADA, AUSTEDO XR, CAPLYTA, APLENZIN.
Industry payments across SC — which companies pay providers there.
